Toth, Peter P <br/><br/>
Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results.  [electronic resource] 

 -  Journal of medical economics  Jul 2017 
 - 749-751 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2017.1327440  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cardiovascular Diseases--economics<br/>Cost-Benefit Analysis--methods<br/>Humans<br/>Hypolipidemic Agents--economics<br/>Models, Econometric<br/>PCSK9 Inhibitors<br/>Quality-Adjusted Life Years<br/>Risk Assessment